share_log

8-K: HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

8-K: HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

8-K:HeartSciences提供最新业务并报告2025财年第二季度财务业绩
美股SEC公告 ·  12/16 16:18

Moomoo AI 已提取核心信息

HeartSciences reported financial results for Q2 FY2025 ended October 31, 2024. The company made significant progress on its MyoVista Insights cloud-native platform, with Phase 1 completion expected by year-end. Discussions are underway for early deployment in test environments in H1 2025. The platform aims to modernize ECG reporting and management systems.The company's MyoVista wavECG device is on track for FDA submission around the end of Q1 2025. HeartSciences is developing AI-ECG algorithms, including a low ejection fraction algorithm licensed from Mount Sinai. The CMS 2025 OPPS final rule includes reimbursement for HeartSciences' AI-ECG algorithms, effective January 2025.As of October 31, 2024, HeartSciences reported cash and cash equivalents of $4.1 million and shareholders' equity of $4.0 million. The company had no revenues during Q2 FY2025. HeartSciences aims to transform ECG technology and expand its clinical utility across various healthcare settings.
HeartSciences reported financial results for Q2 FY2025 ended October 31, 2024. The company made significant progress on its MyoVista Insights cloud-native platform, with Phase 1 completion expected by year-end. Discussions are underway for early deployment in test environments in H1 2025. The platform aims to modernize ECG reporting and management systems.The company's MyoVista wavECG device is on track for FDA submission around the end of Q1 2025. HeartSciences is developing AI-ECG algorithms, including a low ejection fraction algorithm licensed from Mount Sinai. The CMS 2025 OPPS final rule includes reimbursement for HeartSciences' AI-ECG algorithms, effective January 2025.As of October 31, 2024, HeartSciences reported cash and cash equivalents of $4.1 million and shareholders' equity of $4.0 million. The company had no revenues during Q2 FY2025. HeartSciences aims to transform ECG technology and expand its clinical utility across various healthcare settings.
HeartSciences报告了截至2024年10月31日的2025财年第二季度财务结果。公司在其MyoVista Insights云原生平台上取得了重大进展,第一阶段的完成预计在年底前。关于在2025年上半年测试环境中提前部署的讨论正在进行中。该平台旨在现代化心电图报告和管理系统。公司的MyoVista wavECG设备计划在2025年第一季度末提交FDA申请。HeartSciences正在开发人工智能心电图算法,包括一项从西奈山医院获得许可的低射血分数算法。CMS 2025 OPPS最终规则包括对HeartSciences的人工智能心电图算法的报销,生效时间为2025年1月。截至2024年10月31日,HeartSciences报告的现金及现金等价物为410万美元,股东权益为400万美元。公司在2025财年第二季度没有收入。HeartSciences旨在转变心电图科技,并扩大其在各种医疗环境中的临床实用性。
HeartSciences报告了截至2024年10月31日的2025财年第二季度财务结果。公司在其MyoVista Insights云原生平台上取得了重大进展,第一阶段的完成预计在年底前。关于在2025年上半年测试环境中提前部署的讨论正在进行中。该平台旨在现代化心电图报告和管理系统。公司的MyoVista wavECG设备计划在2025年第一季度末提交FDA申请。HeartSciences正在开发人工智能心电图算法,包括一项从西奈山医院获得许可的低射血分数算法。CMS 2025 OPPS最终规则包括对HeartSciences的人工智能心电图算法的报销,生效时间为2025年1月。截至2024年10月31日,HeartSciences报告的现金及现金等价物为410万美元,股东权益为400万美元。公司在2025财年第二季度没有收入。HeartSciences旨在转变心电图科技,并扩大其在各种医疗环境中的临床实用性。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息